NASDAQ: RGLSRegulus Therapeutics Inc Stock
$2.22-0.04 (-1.77%)
Updated Apr 24, 2024
RGLS Price
$2.22
Fair Value Price
$1.09
Market Cap
$145.33M
52 Week Low
$1.08
52 Week High
$3.79
P/E
-1.41x
P/B
6.86x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$30.04M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.45
Operating Cash Flow
-$27M
Beta
0.76
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
RGLS Overview
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RGLS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RGLS ($2.22) is overvalued by 103.08% relative to our estimate of its Fair Value price of $1.09 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RGLS ($2.22) is not significantly undervalued (103.08%) relative to our estimate of its Fair Value price of $1.09 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RGLS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RGLS due diligence checks available for Premium users.
Be the first to know about important RGLS news, forecast changes, insider trades & much more!
RGLS News
Valuation
RGLS fair value
Fair Value of RGLS stock based on Discounted Cash Flow (DCF)
Price
$2.22
Fair Value
$1.09
Overvalued by
103.08%
RGLS ($2.22) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RGLS ($2.22) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RGLS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RGLS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.41x
Industry
15.69x
Market
41.27x
RGLS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.86x
Industry
5.86x
RGLS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RGLS's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.1M
Profit Margin
0%
RGLS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$30.8M
Liabilities
$9.6M
Debt to equity
0.45
RGLS's short-term assets ($28.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RGLS's short-term assets ($28.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RGLS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RGLS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.1M
Investing
$4.9M
Financing
-$873.0k
RGLS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RGLS vs Biotech Stocks
Regulus Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.